Effects Of Kechuanting Acupoint Application On The Remission Of Asthma Rats INF-γ And Other Asth Matic Inhibition Inflammation Factors

Purpose:Observe the effects of kechuanting acupoint application in treating bronchial a sthma on the expression of IFN-γ、IL-2、IL-12study the mechanism of kechuanting Acupoint Application in treating bronchial asthma on the downstream regulatory factors to Thl/Th2as the core of the immune regulation, For clinical prevention and provide t heoretical basis for the remission of bronchial asthma.Method:6-week-old SPF48wistar male rats, weighing160±20g, were randomly divided int o six groups:the normal group (A), asthma model group (B), dexamethasone group (C), false acupoint application group (D), acupoint application group (E), budesonide group (F). Each group of eight rats. Rat model of chronic allergic asthma in the preparation of ovalbumin (OVA). Rat adaptive feeding one week. For the first time to accept sens itization injections on day1, the first two weeks of sensitization phase. The first15da ys to56days of continuous excitation phase (six weeks). Sensitization phase:Day1to B, C, D, E, F rats by intraperitoneal injection of OVA and aluminum hydroxide mixe d solution lml (including OVAlOmg, aluminum hydroxide100mg), note again the first8days of abdominal strengthening sensitization. Excitation phases:the first15days beg ins, B, C, D, E, F group were placed in a closed-owned atomization chamber, to1%OVA solution ultrasonic atomization, every second day,30min. Rats were observed coug hing, wheezing and other reactions.56days until the end of atomization. The first57days starting on C, D, E, F group treatment. Group A, B:Normal feeding and does no t do other processing. C group:Dexamethasone lmg/kg/day, intraperitoneal injection,14days of treatment. D Group:Vaseline patch outside for bilateral Feishu, Pishu, Shensh u, six hours after removal, every day,14days of treatment. E Group:acupoint applicat ion patch outside for bilateral Feishu, Pishu, Shenshu, six hours after removal, every da y,14days of treatment. F group:nebulized budesonide inhalation to20ml,10min/day,14days of treatment.Results:(1) behavioral manifestations of asthma in ratsNormal group rats was normal, steady breathing, no breathlessness and other performance; performance of asthmatic rats vertical hair, dark hair, burnout. When rats had typical asthma nebulizer excited like episodes, manifested as shortness of breath, mouth breathing, sneezing, lips cyanosis, reduced forelimbs lift, nodding breathing, abdominal flaring and slow, etc., and with the excitation frequency increases gradually increased symptoms, fog activity was significantly reduced in rats of late; showed rats initially with asthma characteristics.(2) lung tissue pathology (HE staining) changeIn bronchopulmonary HE staining can be observed in:A normal group:bronchial epithelial integrity, around the shape, alveolar septa and a small amount of blood vessel wall infiltration of inflammatory cells, bronchial secretions little chamber, no wall of fibrous connective tissue and smooth muscle hyperplasia, alveolar morphological rules.B model group:alveolar saw inflammatory cell infiltration, bronchial mucosal edema, increased secretions, luminal narrowing, intraluminal see mucus plug, the part of the bronchial epithelium with partial reduction of wrinkles, bronchial wall and perivascular inflammatory cells see infiltration, bronchial wall thickening.C dexamethasone group:Compared with the model group, bronchial mucus plug cavity decreased epithelial integrity, lung intervals no significant thickening of the bronchial wall of a small amount of inflammatory cell infiltration, fibrous connective tissue and smooth muscle wall no significant proliferation.D false acupoint application groups:similar to the model group, see the alveolar inflammatory cell infiltration, bronchial mucosal edema, increased secretions, luminal narrowing, intraluminal see mucus plug, the part of the bronchial epithelium with partial reduction of wrinkles, bronchial wall and perivascular see eosinophils, monocytes, lymphocytes and plasma cells, bronchial wall thickening.E acupoint application group:Compared with the model group, bronchial mucus plug cavity decreased epithelial integrity intervals have less lung inflammatory cell infiltration, no significant thickening of the bronchial wall of fibrous connective tissue and smooth muscle showed no hyperplasia.F budesonide group:Compared with the model group, bronchial mucus plug cavity decreased epithelial integrity, lung intervals no significant thickening of the bronchial wall of a small amount of inflammatory cell infiltration, fibrous connective tissue and smooth muscle wall have no significant proliferation.(3)①IFN-γ assay results:the model group, false acupoint application group BALF I FN-γ were significantly lower than the normal group, there was a significant difference (P<0.05); Compared with the false acupoint application group, acupoint application gro up increased BALF IFN-γ levels, dexamethasone treatment group, nebulized budesonide treatment group comparison with the model group have elevated levels of the role of I FN-y. Acupoint acupoint application group BALF IFN-γ levels and dexamethasone treat ment group, nebulized budesonide treatment group have no significant difference.②IL-2assay results:the model group, false acupoint application group BALF IL-2we re significantly lower than the normal group, there was a significant difference (P<0.05); Compared with the false acupoint application group, acupoint application group incre ased BALF IL-2levels, dexamethasone treatment group, nebulized budesonide treatment group comparison with the model group have elevated levels of IL-2effect. Acupoint a pplication group BALF IL-2levels and dexamethasone treatment group, nebulized budes onide treatment group have no significant difference.③IL-12assay results:false acupoint application group of BALF IL-12were significant ly lower than the normal group, there was a significant difference (P<0.05); Compare d with the false acupoint application group, dexamethasone treatment group, nebulized bu desonide treatment group have elevated levels of IL-12effect (P<0.05), acupoint appli cation group increased BALF IL-12levels but not significantly different.Conclusion:From the experimental results, the Kechuanting acupoint application can incr ease asthma in experimental rat serum IFN-γ、IL-2、IL-12levels, suggesting acupoint application of asthmatic rats main mechanism by blocking or inhibiting the activation of Th2cells secrete Thl cell activation or excited, thereby adjusting the Thl/Th2imbalan ce, to inhibit airway inflammation, airway rat model to reduce the thickness ofthe film, thickness and fibrous tissue small airway smooth muscle thickness to achievetherapeuti c effects of asthma; Kechuanting acupoint application effect on the secretionof IL-12is not significant, which is the mechanism needs further study.